Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Operating Expenses: 2022-2024

Historic Other Operating Expenses for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Dec 2024 value amounting to $160.8 million.

  • Amylyx Pharmaceuticals' Other Operating Expenses rose 609.31% to $37.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $193.0 million, marking a year-over-year increase of 921.30%. This contributed to the annual value of $160.8 million for FY2024, which is 532.19% up from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Other Operating Expenses stood at $160.8 million for FY2024, which was up 532.19% from $25.4 million recorded in FY2023.
  • Amylyx Pharmaceuticals' 5-year Other Operating Expenses high stood at $160.8 million for FY2024, and its period low was $3.0 million during FY2022.
  • For the 3-year period, Amylyx Pharmaceuticals' Other Operating Expenses averaged around $63.1 million, with its median value being $25.4 million (2023).
  • Data for Amylyx Pharmaceuticals' Other Operating Expenses shows a peak YoY skyrocketed of 750.02% (in 2023) over the last 5 years.
  • Over the past 3 years, Amylyx Pharmaceuticals' Other Operating Expenses (Yearly) stood at $3.0 million in 2022, then soared by 750.02% to $25.4 million in 2023, then skyrocketed by 532.19% to $160.8 million in 2024.